Post Profile

Diabetes Drug for Addiction Treatment

A relatively new class of drugs, glucagon-like peptide-1 (GLP-1) receptor agonists, have had much success in the treatment of type 2 diabetes. Now, these drugs may offer support in the treatment of addiction and drug abuse. A new study, published in Translational Psychiatry, reports that GLP-1 receptors may be a target for treating drug abuse. […]
read more


Related Posts

Promising drug candidates, biased agonists, developed for pain and addiction

Health : Medical News Today

Scientists from the Florida campus of The Scripps Research Institute (TSRI) have described a pair of drug candidates that advance the search for new treatments for pain, addiction and other disorders.The two new drug scaffolds, desc...

New Target For Drug Addiction Treatment Suggested By Collaborative Preclinical Efficacy Studies

Health : Medical News Today

In preclinical studies, researchers at SRI International and Astraea Therapeutics have recently evaluated the role of a new drug receptor target that shows promise for the treatment of drug addiction. This potential new drug target ...

GSK Announces Regulatory Submission Of Its Type 2 Diabetes Drug Albigultide

Health : Medical News Today

GlaxoSmithKline has announced a regulatory submission to the U.S. Food and Drug Administration for its type 2 diabetes drug called albigultide. The drug, which is taken once-weekly, is a a glucagon-like peptide-1 agonist (GLP-1 agon...

Drug deaths: Western drug policies are failing

Academics / General Science : Science Codex

England has a failing national drug policy, shown in a steep rise in drug related deaths since 2012, warn public health experts in The BMJ this week. Oddly, they claim fiscal responsibility and say giving addicts more free housing w...

DARA Announces Positive Results From Phase 1b Clinical Study For The Treatment Of Type 2 Diabetes

Health : Medical News Today

DARA BioSciences, Inc. (NASDAQ: DARA), announces the positive results from a successfully completed Phase 1b clinical study for DB959, its peroxisome proliferator activated receptor (PPAR)-delta/gamma agonist, a non-TZD oral drug in...


Copyright © 2016 Regator, LLC